Literature DB >> 26598511

Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy.

Pankaj Shende1, Lifen Xu1, Christian Morandi1, Laura Pentassuglia1, Philippe Heim1, Sonia Lebboukh1, Corinne Berthonneche2, Thierry Pedrazzini2, Beat A Kaufmann1, Michael N Hall3, Markus A Rüegg3, Marijke Brink4.   

Abstract

AIMS: Mammalian target of rapamycin (mTOR), a central regulator of growth and metabolism, has tissue-specific functions depending on whether it is part of mTOR complex 1 (mTORC1) or mTORC2. We have previously shown that mTORC1 is required for adaptive cardiac hypertrophy and maintenance of function under basal and pressure-overload conditions. In the present study, we aimed to identify functions of mTORC2 in the heart. METHODS AND
RESULTS: Using tamoxifen-inducible cardiomyocyte-specific gene deletion, we generated mice deficient for cardiac rapamycin-insensitive companion of mTOR (rictor), an essential and specific component of mTORC2. Under basal conditions, rictor deficiency did not affect cardiac growth and function in young mice and also had no effects in adult mice. However, transverse aortic constriction caused dysfunction in the rictor-deficient hearts, whereas function was maintained in controls after 1 week of pressure overload. Adaptive increases in cardiac weight and cardiomyocyte cross-sectional area, fibrosis, and hypertrophic and metabolic gene expression were not different between the rictor-deficient and control mice. In control mice, maintained function was associated with increased protein levels of rictor, protein kinase C (PKC)βII, and PKCδ, whereas rictor ablation abolished these increases. Rictor deletion also significantly decreased PKCε at baseline and after pressure overload. Our data suggest that reduced PKCε and the inability to increase PKCβII and PKCδ abundance are, in accordance with their known function, responsible for decreased contractile performance of the rictor-deficient hearts.
CONCLUSION: Our study demonstrates that mTORC2 is implicated in maintaining contractile function of the pressure-overloaded male mouse heart. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Heart failure; Hypertrophy; Metabolism; Signal transduction

Mesh:

Substances:

Year:  2015        PMID: 26598511     DOI: 10.1093/cvr/cvv252

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  27 in total

Review 1.  Adrenoceptor regulation of the mechanistic target of rapamycin in muscle and adipose tissue.

Authors:  Ling Yeong Chia; Bronwyn A Evans; Saori Mukaida; Tore Bengtsson; Dana S Hutchinson; Masaaki Sato
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

Review 2.  New Insights Into the Role of mTOR Signaling in the Cardiovascular System.

Authors:  Sebastiano Sciarretta; Maurizio Forte; Giacomo Frati; Junichi Sadoshima
Journal:  Circ Res       Date:  2018-02-02       Impact factor: 17.367

3.  Ghrelin protected neonatal rat cardiomyocyte against hypoxia/reoxygenation injury by inhibiting apoptosis through Akt-mTOR signal.

Authors:  Lifeng Wang; Yingjie Lu; Xian Liu; Xiaoyun Wang
Journal:  Mol Biol Rep       Date:  2017-03-09       Impact factor: 2.316

Review 4.  Oncometabolic Tracks in the Heart.

Authors:  Heinrich Taegtmeyer; Anja Karlstaedt; Meredith L Rees; Giovanni Davogustto
Journal:  Circ Res       Date:  2017-01-20       Impact factor: 17.367

5.  HTR2A promotes the development of cardiac hypertrophy by activating PI3K-PDK1-AKT-mTOR signaling.

Authors:  Weinian Gao; Na Guo; Shuguang Zhao; Ziying Chen; Wenli Zhang; Fang Yan; Hongjuan Liao; Kui Chi
Journal:  Cell Stress Chaperones       Date:  2020-06-09       Impact factor: 3.667

6.  Small molecule QF84139 ameliorates cardiac hypertrophy via activating the AMPK signaling pathway.

Authors:  Xu-Xia Li; Peng Zhang; Yang Yang; Jing-Jing Wang; Yan-Jun Zheng; Ji-Liang Tan; Shen-Yan Liu; Yong-Ming Yan; You-Yi Zhang; Yong-Xian Cheng; Huang-Tian Yang
Journal:  Acta Pharmacol Sin       Date:  2021-05-09       Impact factor: 6.150

Review 7.  The complex network of mTOR signalling in the heart.

Authors:  Sebastiano Sciarretta; Maurizio Forte; Giacomo Frati; Junichi Sadoshima
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 10.787

8.  Elimination of endogenous high molecular weight FGF2 prevents pressure-overload-induced systolic dysfunction, linked to increased FGFR1 activity and NR1D1 expression.

Authors:  Navid Koleini; Barbara E Nickel; Raghu S Nagalingam; Natalie M Landry; Robert R Fandrich; David Y C Cheung; Ian M Dixon; Michael P Czubryt; Davinder S Jassal; Peter A Cattini; Elissavet Kardami
Journal:  Cell Tissue Res       Date:  2021-05-31       Impact factor: 5.249

9.  The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy.

Authors:  Zhihua Wang; Xiao-Jing Zhang; Yan-Xiao Ji; Peng Zhang; Ke-Qiong Deng; Jun Gong; Shuxun Ren; Xinghua Wang; Iris Chen; He Wang; Chen Gao; Tomohiro Yokota; Yen Sin Ang; Shen Li; Ashley Cass; Thomas M Vondriska; Guangping Li; Arjun Deb; Deepak Srivastava; Huang-Tian Yang; Xinshu Xiao; Hongliang Li; Yibin Wang
Journal:  Nat Med       Date:  2016-09-12       Impact factor: 53.440

10.  High-density lipoprotein protects cardiomyocytes from oxidative stress via the PI3K/mTOR signaling pathway.

Authors:  Manabu Nagao; Ryuji Toh; Yasuhiro Irino; Hideto Nakajima; Toshihiko Oshita; Shigeyasu Tsuda; Tetsuya Hara; Masakazu Shinohara; Tatsuro Ishida; Ken-Ichi Hirata
Journal:  FEBS Open Bio       Date:  2017-08-14       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.